Contract Services
Samsung Biologics Reports Second Quarter 2022 Financial Results
Released consolidated financial position of the company based on its full acquisition of Samsung Bioepis completed on April 20, 2022 Achieved recor...
July 28, 2022 | News
Ozgene and Gen-H partner on Ozgene’s new OzBIG targeted humanization capability
Ozgene and Gen-H are pleased to announce our working partnership supporting Ozgene’s new OzBIG capability. Ozgene Pty Ltd is a privately held CRO bas...
July 25, 2022 | News
WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore
This investment will establish a cutting-edge, fully integrated CRDMO center in Singapore, including a research and development service center and large-...
July 20, 2022 | News
Samsung Biologics to purchase land for its second Bio Campus
Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 Plans to build Multi-Modal Plant, Open Innovation,...
July 19, 2022 | News
Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial
Dr. Shaoliang Chen, Chair of Pulnovo Medical's Scientific Advisory Board and pioneer of the PADN technology, attended the meeting and presented the co...
July 18, 2022 | News
GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs
Through this agreement, both companies will strategically cooperate in the overall development process, such as discovery, manufacturing, and clinical tria...
July 15, 2022 | News
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea
SK bioscience and GSK recently announced the successful authorization:SK bioscience announced that 'SKYCovione(TM),' South Korea's first COVID-19 vaccine c...
July 14, 2022 | News
GenScript ProBio Signs MOU to Form Strategic Partnership with ACT Therapeutics to Development of New CAR-T Cell Therapies
GenScript ProBio and ACT Therapeutics are in the process of signing a contract for plasmid and virus vector development and production for the first pipe...
July 13, 2022 | News
'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report
Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy. Details n...
July 12, 2022 | News
WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates
Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process developm...
July 08, 2022 | News
WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility
WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Chan...
July 07, 2022 | News
WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products
WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG14 fac...
July 05, 2022 | News
Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Shiga, Japan
The new blister packaging equipment is identical to that available across Catalent's clinical supply services network, offering maximum access and flexibil...
June 30, 2022 | News
WuXi STA Opens A High-Potency API Plant
The new plant adopts advanced isolation technologies with the capability to handle potent compounds with Occupational Exposure Limit (OEL) as low as 10 ng/...
June 29, 2022 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
